Compare Etsy Inc (ETSY) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Etsy Inc vs Novartis AG — how do they compare? Etsy Inc trades at $79.73 (market cap $7.29B), while Novartis AG trades at $154.71 (market cap $295.37B). The key difference: Novartis AG is far larger — about 40.5× Etsy Inc's market cap, and Novartis AG pays a 3.07% dividend while Etsy Inc pays none. Which is the better fit depends on your goals.
| ETSY | NVS | |
|---|---|---|
Market Cap | $7.29B | $295.37B |
Sector | Consumer Cyclical | Health |
52-Week High | $86.47 | $168.62 |
52-Week Low | $44.05 | $119.31 |
Enterprise Value | $9.25B | $336.69B |
Dividend Yield | — | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ETSY trades at $79.53, down 1.08% on the day, with a bearish technical signal but strong recent earnings beats. The company reported Q2 2026 EPS of $0.98, beating expectations, and announced a $2 billion share buyback alongside a 12% workforce reduction to boost efficiency. Revenue trends show modest growth, with 2025 revenue at $2.88 billion, though net income margin declined to 5.65% from prior years.
Outlook is mixed: analyst consensus is a Buy with a $85.71 price target, citing GMS growth and cost initiatives, but risks include high debt, margin pressure, and competitive threats. The stock's current price near support at $78 offers potential upside if operational improvements sustain.
Novartis (NVS) trades at $152.41, down 2.79% today, with technical indicators showing neutral momentum near key support at $152. The company reported strong Q2 2026 earnings that beat expectations, driven by oncology drug performance, while maintaining a robust 22.5% net margin and $56.7B in revenue. Recent institutional buying activity and a predominantly Hold analyst consensus reflect cautious optimism amid patent expiration headwinds.
The outlook balances strong fundamentals and pipeline progress against generic competition risks. Investment appeal lies in dividend stability and new drug growth, though Entresto sales decline and U.S. pricing pressures require monitoring. The stock presents a defensive opportunity with moderate upside potential if newer therapies continue outperforming.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Etsy Inc
Etsy operates a top-10 e-commerce marketplace operator in the U.S. and the U.K., with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $13.5 billion in 2021 consolidated gross merchandise volume, the firm has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. As of the end of 2021, the firm connected more than 96 million buyers and more than 7.5 million sellers on its marketplace properties: Etsy, Reverb (musical equipment), Elo7 (crafts in Brazil), and Depop (clothing resale).
Read more on ETSY →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
